Identification, Screening, and Comprehensive Evaluation of Novel DPP-IV Inhibitory Peptides from the Tilapia Skin Gelatin Hydrolysate Produced Using Ginger Protease

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Dec 23

PMID 36551294

Authors

Wei Liu

Xinyu Wang

Wenning Yang

Xueyan Li

Dongying Qi

Hongjiao Chen

Huining Liu

Shuang Yu

Yanli Pan

Yang Liu

Guopeng Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Inhibition of dipeptidyl peptidase-IV (DPP-IV) is an effective therapy for treating type II diabetes (T2D) that has been widely applied in clinical practice. We aimed to evaluate the DPP-IV inhibitory properties of ginger protease hydrolysate (GPH) and propose a comprehensive approach to screen and evaluate DPP-IV inhibitors.

Methods: We evaluated the in vitro inhibitory properties of fish skin gelatin hydrolysates produced by five proteases, namely, neutral protease, alkaline protease, bromelain, papain, and ginger protease, toward DPP-IV. We screened the most potent DPP-IV inhibitory peptide (DIP) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) coupled with in silico analysis. Next, surface plasmon resonance (SPR) technology was innovatively introduced to explore the interactions between DPP-IV and DIP, as well as the IC. Furthermore, we performed oral administration of DIP in rats to study its in vivo absorption.

Results: GPH displayed the highest degree of hydrolysis (20.37%) and DPP-IV inhibitory activity (65.18%). A total of 292 peptides from the GPH were identified using LC-MS/MS combined with de novo sequencing. Gly-Pro-Hyp-Gly-Pro-Pro-Gly-Pro-Gly-Pro (GPXGPPGPGP) was identified as the most potent DPP-IV inhibitory peptide after in silico screening (Peptide Ranker and molecular docking). Then, the in vitro study revealed that GPXGPPGPGP had a high inhibitory effect on DPP-IV (IC: 1012.3 ± 23.3 μM) and exhibited fast kinetics with rapid binding and dissociation with DPP-IV. In vivo analysis indicated that GPXGPPGPGP was not absorbed intact but partially, in the form of dipeptides and tripeptides.

Conclusion: Overall, the results suggested that GPH would be a natural functional food for treating T2D and provided new ideas for searching and evaluating potential antidiabetic compounds. The obtained GPXGPPGPGP can be structurally optimized for in-depth evaluation in animal and cellular experiments.

Citing Articles

Chlorogenic acid: a review on its mechanisms of anti-inflammation, disease treatment, and related delivery systems.

Huang J, Xie M, He L, Song X, Cao T Front Pharmacol. 2023; 14:1218015.

PMID: 37781708 PMC: 10534970. DOI: 10.3389/fphar.2023.1218015.

-Derived Extracellular Vesicles Attenuate Bleomycin-Induced Pulmonary Fibrosis Trough Antioxidant, Anti-Inflammatory and Protease Activity in a Mouse Model.

Ramirez-Hernandez A, Reyes-Jimenez E, Velazquez-Enriquez J, Santos-Alvarez J, Soto-Guzman A, Castro-Sanchez L Cells. 2023; 12(14).

PMID: 37508515 PMC: 10378408. DOI: 10.3390/cells12141852.

References

Zhang J, Xin L, Shan B, Chen W, Xie M, Yuen D . PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol Cell Proteomics. 2011; 11(4):M111.010587. PMC: 3322562. DOI: 10.1074/mcp.M111.010587. View

Taga Y, Hayashida O, Kusubata M, Ogawa-Goto K, Hattori S . Production of a novel wheat gluten hydrolysate containing dipeptidyl peptidase-IV inhibitory tripeptides using ginger protease. Biosci Biotechnol Biochem. 2017; 81(9):1823-1828. DOI: 10.1080/09168451.2017.1345615. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. PMC: 6227754. DOI: 10.1016/S0140-6736(18)32279-7. View

Howse P, Chibrikova L, Twells L, Barrett B, Gamble J . Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016; 68(5):733-742. DOI: 10.1053/j.ajkd.2016.06.014. View

Li S, Liu L, He G, Wu J . Molecular targets and mechanisms of bioactive peptides against metabolic syndromes. Food Funct. 2017; 9(1):42-52. DOI: 10.1039/c7fo01323j. View

Taga Y, Kusubata M, Ogawa-Goto K, Hattori S . Efficient Absorption of X-Hydroxyproline (Hyp)-Gly after Oral Administration of a Novel Gelatin Hydrolysate Prepared Using Ginger Protease. J Agric Food Chem. 2016; 64(14):2962-70. DOI: 10.1021/acs.jafc.6b00609. View

Taga Y, Hayashida O, Ashour A, Amen Y, Kusubata M, Ogawa-Goto K . Characterization of Angiotensin-Converting Enzyme Inhibitory Activity of X-Hyp-Gly-Type Tripeptides: Importance of Collagen-Specific Prolyl Hydroxylation. J Agric Food Chem. 2018; 66(33):8737-8743. DOI: 10.1021/acs.jafc.8b03648. View

Copeland R, Pompliano D, Meek T . Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006; 5(9):730-9. DOI: 10.1038/nrd2082. View

Adibi S . The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology. 1997; 113(1):332-40. DOI: 10.1016/s0016-5085(97)70112-4. View

10.

Shimizu K, Sato M, Zhang Y, Kouguchi T, Takahata Y, Morimatsu F . The bioavailable octapeptide Gly-Ala-Hyp-Gly-Leu-Hyp-Gly-Pro stimulates nitric oxide synthesis in vascular endothelial cells. J Agric Food Chem. 2010; 58(11):6960-5. DOI: 10.1021/jf100388w. View

11.

Yan W . Binding time--not just affinity--gains stature in drug design. Nat Med. 2015; 21(6):545. DOI: 10.1038/nm0615-545. View

12.

Li C, Liu X, Bai L, Yu Q, Zhang Q, Yu P . Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr. 2014; 6:69. PMC: 4050987. DOI: 10.1186/1758-5996-6-69. View

13.

Li N, Wang L, Jiang B, Li X, Guo C, Guo S . Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Eur J Med Chem. 2018; 151:145-157. DOI: 10.1016/j.ejmech.2018.03.041. View

14.

Bleakley S, Hayes M, O Shea N, Gallagher E, Lafarga T . Predicted Release and Analysis of Novel ACE-I, Renin, and DPP-IV Inhibitory Peptides from Common Oat (Avena sativa) Protein Hydrolysates Using in Silico Analysis. Foods. 2017; 6(12). PMC: 5742776. DOI: 10.3390/foods6120108. View

15.

Patel B, Ghate M . Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014; 74:574-605. DOI: 10.1016/j.ejmech.2013.12.038. View

16.

Zhang M, Zhu L, Wu G, Liu T, Qi X, Zhang H . Food-derived dipeptidyl peptidase IV inhibitory peptides: Production, identification, structure-activity relationship, and their potential role in glycemic regulation. Crit Rev Food Sci Nutr. 2022; 64(8):2053-2075. DOI: 10.1080/10408398.2022.2120454. View

17.

Hatanaka T, Inoue Y, Arima J, Kumagai Y, Usuki H, Kawakami K . Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food Chem. 2012; 134(2):797-802. DOI: 10.1016/j.foodchem.2012.02.183. View

18.

Choi K, Laursen R . Amino-acid sequence and glycan structures of cysteine proteases with proline specificity from ginger rhizome Zingiber officinale. Eur J Biochem. 2000; 267(5):1516-26. DOI: 10.1046/j.1432-1327.2000.01152.x. View

19.

Hussain H, Abbas G, Green I, Ali I . Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018). Expert Opin Ther Pat. 2019; 29(7):535-553. DOI: 10.1080/13543776.2019.1632290. View

20.

Mudgil P, Kamal H, Yuen G, Maqsood S . Characterization and identification of novel antidiabetic and anti-obesity peptides from camel milk protein hydrolysates. Food Chem. 2018; 259:46-54. DOI: 10.1016/j.foodchem.2018.03.082. View